Payment overview · 2025
General Payments
$38.29
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mark Ende, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PETERSBURG, VA · NPI 1528152824
Verified facts
What the public records show
CMS Open Payments records show Mark Ende, M.D. received $38.29 in general payments during 2025 across 2 reported records.
Inspire Medical Systems, Inc. accounted for 62.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.01 | 62.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.28 | 37.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.29 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
159 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 136 |
| Losartan Potassium | Losartan Potassium | 458 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 89 |
| Furosemide | Furosemide | 383 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 372 | 83 |
| Gabapentin | Gabapentin | 326 | 80 |
| Tramadol Hcl | Tramadol Hcl | 304 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 60 |
| Lisinopril | Lisinopril | 282 | 50 |
| Omeprazole | Omeprazole | 272 | 65 |
| Potassium Chloride | Potassium Chloride | 256 | 55 |
| Metformin Hcl | Metformin Hcl | 243 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 221 | 45 |
| Famotidine | Famotidine | 210 | 51 |
| Eliquis | Apixaban | 203 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 45 |
| Simvastatin | Simvastatin | 192 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 38 |
| Montelukast Sodium | Montelukast Sodium | 165 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 161 | 28 |
| Farxiga | Dapagliflozin Propanediol | 159 | 32 |
| Allopurinol | Allopurinol | 156 | 34 |
| Alprazolam | Alprazolam | 152 | 24 |
| Azithromycin | Azithromycin | 150 | 102 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 34 |
| Trazodone Hcl | Trazodone Hcl | 137 | 34 |
| Lorazepam | Lorazepam | 133 | 22 |
| Glimepiride | Glimepiride | 132 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 130 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 27 |
| Carvedilol | Carvedilol | 111 | 24 |
| Methylprednisolone | Methylprednisolone | 111 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 25 |
| Jardiance | Empagliflozin | 104 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 90 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 19 |
| Januvia | Sitagliptin Phosphate | 78 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | suppressed |
| Nifedipine Er | Nifedipine | 72 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 17 |
| Bupropion Xl | Bupropion Hcl | 64 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 14 |
| Mupirocin | Mupirocin | 60 | 34 |
| Celecoxib | Celecoxib | 59 | 13 |
| Warfarin Sodium | Warfarin Sodium | 58 | 11 |
| Prednisone | Prednisone | 57 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 56 | 44 |
| Meloxicam | Meloxicam | 56 | 13 |
| Spironolactone | Spironolactone | 56 | 14 |
| Diazepam | Diazepam | 54 | suppressed |
| Ozempic | Semaglutide | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 11 |
| Glipizide | Glipizide | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 11 |
| Clonazepam | Clonazepam | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | 14 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Nexletol | Bempedoic Acid | 28 | 11 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 17 |
| Nitroglycerin | Nitroglycerin | 25 | 11 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Colchicine | Colchicine | 22 | suppressed |
| Lactulose | Lactulose | 22 | 11 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | 15 |
| Nadolol | Nadolol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Tradjenta | Linagliptin | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.29 · 2 records | Inspire Medical Systems, Inc. | FARXIGA, INSPIRE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error